

Jing Wang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1285039/publications.pdf>

Version: 2024-02-01

15
papers

776
citations

1040056

9
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

1027
citing authors

#	ARTICLE	IF	CITATIONS
1	PARP inhibitor resistance: the underlying mechanisms and clinical implications. <i>Molecular Cancer</i> , 2020, 19, 107.	19.2	235
2	PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. <i>Redox Biology</i> , 2021, 42, 101928.	9.0	150
3	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018, 78, 742-757.	0.9	98
4	TRPM7 promotes the epithelialâ€mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 106.	8.6	90
5	Circular RNA circTNPO3 Regulates Paclitaxel Resistance of Ovarian Cancer Cells by miR-1299/NEK2 Signaling Pathway. <i>Molecular Therapy - Nucleic Acids</i> , 2020, 21, 780-791.	5.1	49
6	TRPM7 is required for ovarian cancer cell growth, migration and invasion. <i>Biochemical and Biophysical Research Communications</i> , 2014, 454, 547-553.	2.1	48
7	Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. <i>Modern Pathology</i> , 2020, 33, 29-37.	5.5	28
8	Overexpression of TRPM7 is Associated with Poor Prognosis in Human Ovarian Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , 2014, 15, 3955-3958.	1.2	27
9	TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1 α degradation. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022, 41, 44.	8.6	25
10	Development of a novel transcription factors-related prognostic signature for serous ovarian cancer. <i>Scientific Reports</i> , 2021, 11, 7207.	3.3	8
11	Comparison of survival outcomes of neoadjuvant therapy and direct surgery in IB2/IIA2 cervical adenocarcinoma: a retrospective study. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1247-1255.	1.7	7
12	An effective AKT inhibitor-PARP inhibitor combination therapy for recurrent ovarian cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 683-695.	2.3	6
13	Effect of fluconazole on the pharmacokinetics of fuzuloparib: an open-label, crossover study in Chinese healthy male volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 141-148.	2.3	4
14	<i>ZNF582</i> promoter methylation predicts cervical cancer radiosensitivity and ZNF582 protein overexpression reduces radiosensitivity by cell cycle arrest in S phase. <i>Epigenetics</i> , 2022, 17, 1786-1799.	2.7	1
15	Research progress in the treatment of partial platinum-sensitive recurrent ovarian cancer. <i>Journal of Central South University (Medical Sciences)</i> , 2021, 46, 644-652.	0.1	0